Gpr17 Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GPR17 neurons are a specialized population of neurons that express the GPR17 receptor, a P2Y-like G-protein coupled receptor that plays a critical role in oligodendrocyte differentiation, myelination, and white matter maintenance. While GPR17 is primarily studied on oligodendrocyte precursor cells (OPCs), emerging research indicates that GPR17 is also expressed on specific neuronal populations where it participates in purinergic signaling cascades that regulate neural circuit function and repair mechanisms. [1]
GPR17 belongs to the P2Y receptor family, which responds to extracellular nucleotides such as UDP and UTP. This receptor has emerged as a key regulator of the oligodendrocyte lineage and represents a potential therapeutic target for demyelinating diseases and white matter disorders. [2]
GPR17 is a seven-transmembrane domain G-protein coupled receptor (GPCR) that couples primarily to Gi/o proteins, leading to inhibition of adenylate cyclase and decreased cAMP production. The receptor has distinct binding sites for: [3]
GPR17 activation triggers multiple intracellular signaling cascades: [4]
The GPR17 gene (GPR17) is located on chromosome 14q21.3 and encodes a 367-amino acid protein. Expression is developmentally regulated, with high levels in embryonic and early postnatal stages, decreasing in adulthood. [5]
GPR17-expressing neurons are found in: [6]
GPR17 neurons interface closely with: [7]
GPR17 activity is modulated by:
During embryogenesis, GPR17 expression marks the emergence of oligodendrocyte lineage cells from the ventricular and subventricular zones. The receptor appears around E12.5-E14.5 in mice, coinciding with the specification of oligodendrocyte progenitors.
In the postnatal brain, GPR17+ cells transition through distinct stages:
GPR17 dysfunction is strongly implicated in demyelinating diseases:
GPR17 plays a role in AD pathophysiology:
In PD, GPR17 may contribute to:
Following cerebral ischemia:
GPR17 signaling alterations have been observed in ALS models, potentially affecting:
GPR17 represents a promising drug target:
Currently, no GPR17-targeted therapies are in clinical trials, but preclinical studies show promise for:
GPR17 research utilizes:
GPR17 expression may serve as a biomarker for:
](/mechanisms/white-matter
--purinergic-signaling
--remyelination)## Background
The study of Gpr17 Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Targeting GPR17 for demyelinating diseases (Science Translational Medicine, 2018). 2018. ↩︎
Remyelination strategies targeting GPR17 (Nature Reviews Neurology, 2021). 2021. ↩︎
White matter dysfunction in Alzheimer's disease (Acta Neuropathologica, 2019). 2019. ↩︎
GPR17 knockout mouse phenotype (Journal of Neuroscience, 2017). 2017. ↩︎
Therapeutic modulation of GPR17 (Pharmacological Reviews, 2022). 2022. ↩︎